- 04/27/2020
- eisai selected as most honored company and the first place of the sector in “the all-japan executive team (best ir company ranking)” by institutional investor magazine
- 04/01/2020
- eisai and seikagaku enter into agreement for the co-development and marketing alliance of si-613, a treatment of osteoarthritis, in china
- 03/27/2020
- the 6th eisai china’s give forum (webinar) held successfully
- 03/26/2020
- eisai submits marketing authorization application in japan for anticancer agent denileukin diftitox (genetic recombinant) for cutaneous t-cell lymphoma and peripheral t-cell lymphoma
- 03/22/2020
- 2020 eisai empowering neurology’s future summit (online) kicks off
- 03/02/2020
- eisai china escorts you to tide over the crisis
- 02/25/2020
- eisai and fuji yakuhin conclude license agreement concerning the development and distribution of dotinurad, a treatment for hyperuricemia and gout, in china
- 02/21/2020
- eisai receives the president’s award of the japan techno-economics society at the 8th technology management and innovation awards
- 01/28/2020
- 01/10/2020
- launch of anticancer agent halaven® in china
